HLA-C and melanoma: A non-exhaustive list (reviewed in detail in Pearlman et al. [123]) of public neoantigens within oncogenic drivers for which TIL reactivity has been demonstrated include: CDK4 R24C restricted by HLA-A*02 in melanoma [31]; BCR/ABL b3a2 junction restricted by HLA-A*03 in CML [23]; BRAF V600E restricted by HLA-A*02:01, -B*27:05, HLA-DRB1*04 and -DQB1*03 in melanoma [50,114,126], and KRAS G12C/D/V restricted by HLA-C*08 and HLA-DRB1*07 in pancreatic, colorectal and endometrial cancers [127,128,129,130].